Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
Pre-Market: $29.13 +0.04 (0.14%) 9:14 AM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
Pre-Market: $29.13 +0.04 (0.14%) 9:14 AM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Novavax (NVAX) Down on Q1 Earnings and Sales Lagging Estimates
by Zacks Equity Research
Novavax (NVAX) misses on both earnings and sales for the first quarter of 2022. Its shares decline in after-hours trading following the result announcement.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
J&J (JNJ) Updates COVID Jab Label to Include Blood Clot Risk
by Zacks Equity Research
J&J's (JNJ) decision to update the label of its COVID-19 vaccine came on the heels of the FDA's decision to limit the authorized use of its vaccine due to the risk of TTS.
Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates
by Zacks Equity Research
Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.
Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track
by Zacks Equity Research
Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
BioNTech (BNTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) first-quarter earnings call, investors' focus is expected to be on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.
Pfizer (PFE) Q1 Earnings & Sales Miss Estimates, Stock Down
by Zacks Equity Research
Pfizer (PFE) misses estimates for Q1 earnings and sales. It did not raise its sales guidance for 2022. Stock declines.
Fed's Crucial FOMC Meeting in Focus
by Zacks Equity Research
Fed's Crucial FOMC Meeting in Focus.
Amid a Big Week for the U.S. Economy, PFE, BP, EL Report
by Mark Vickery
Ahead of today's opening bell, we're in the green again, but only dipping a toe in the water just yet.
Pfizer (PFE) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of -2.41% and 3.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More
by Zacks Equity Research
Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.
How Will Pfizer's (PFE) Key Drugs Perform in Q1 Earnings?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 products are likely to have driven sales in the first quarter.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down
by Zacks Equity Research
Bristol-Myers (BMY) earnings beat estimates in the first quarter of 2022. Sales jump year over year on the back of Eliquis and new products.
Pfizer (PFE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the first quarter.
Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.
AbbVie (ABBV) Tops Q1 Earnings Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 0.32% and 0.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 18.23% and 5.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Innoviva (INVA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Innoviva (INVA) delivered earnings and revenue surprises of 5% and 76.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $49.03, marking a +0.16% move from the previous day.
Pfizer (PFE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.